首页>投融资
ANPAC BiO
上市后再融资
Anpac Bio-Medical Science Co Ltd is a biotechnology company focused on early cancer screening and detection.In March 2023, the company had announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares (“ADSs”), pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.In February 2023, Anpac Bio-Medical Science Co Ltd through a subsidiary, Fresh Technology Inc entered into a definitive stock purchase agreement to acquire Fresh2 Ecommerce Inc.In July 2021, AnPac Bio-Medical Science Co had entered into an agreement with Advanced Life Therapeutics Co Ltd.In March 2023, Anpac Bio-Medical Science Co Ltd announced the private placement of 16,666,665 newly issued Class A ordinary shares of the company at a price of US$0.30 per ordinary share with gross proceeds of US$5 million.In January 2023, AnPac Bio-Medical Science announced sign
基本信息
-
公司全称Anpac Bio-Medical Science Co Ltd
-
类型体外疾病检测设备研发商
-
产业领域药品研发/制造、器械/设备、试剂/耗材
-
公司人数15~50人
-
地址2260 Clove Dr. Suite 127 San Jose California 95128; US;
-
联系电话1(267)810-6776
-
邮箱Info@AnpacBio.com
-
成立时间2010-01-01
投融资
-
2023-04-06上市后再融资300万美元未透露
-
2021-11-10增发未透露未透露
-
2020-10-07上市后再融资800万美元未透露
-
2020-10-01上市后再融资700万美元Keystone Capital Partners
-
2020-01-31上市1600万美元未透露
-
2015-12-27B轮200万美元未透露
-
2015-08-19A轮数百万美元未透露
- 加载更多
相关投融资企业
战略投资
Sofie Biosciences is a diagnostics company focused on developing technologies for PET in vivo molecular imaging.In May 2017, Sofie Biosciences entered into a definitive agreement under which it would buy Zevacor Pharma and its high-performance manufacturing and distribution network of PET imaging diagnostics and radio-therapeutics. The transaction was subject to closing conditions, which were expected to finalize in the next 60 to 90 days. In September 2017, the acquisition was completed to form SOFIE.In June 2016, the company completed a $3.7 million financing, representing an oversubscription of nearly $1 million
种子轮
Heranova Lifesciences是一家旨在为女性健康问题提供综合创新解决方案的医疗科技公司。公司计划通过整合诊断、药物、器械和数据，一站式解决妇产科领域未满足的医疗需求。公司也正积极开展针对内异症和妇科炎症的创新药物早期开发，并与全球合作伙伴共同拓展其他关键妇产科适应症的创新解决方案。
上市后再融资
Anpac Bio-Medical Science Co Ltd is a biotechnology company focused on early cancer screening and detection.In March 2023, the company had announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares (“ADSs”), pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.In February 2023, Anpac Bio-Medical Science Co Ltd through a subsidiary, Fresh Technology Inc entered into a definitive stock purchase agreement to acquire Fresh2 Ecommerce Inc.In July 2021, AnPac Bio-Medical Science Co had entered into an agreement with Advanced Life Therapeutics Co Ltd.In March 2023, Anpac Bio-Medical Science Co Ltd announced the private placement of 16,666,665 newly issued Class A ordinary shares of the company at a price of US$0.30 per ordinary share with gross proceeds of US$5 million.In January 2023, AnPac Bio-Medical Science announced sign
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息